glp·helper
glphelper.com/semaglutide/north-carolina/sanford
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Sanford, NC

Verified Semaglutide providers in Sanford, NC. Checked against the NPI registry, never ranked by who pays us.[7]

city providers
25
as of today
§ 02Provider directory: North Carolina
25 of 25 shown

Find a Semaglutide provider in North Carolina.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by North Carolina city · /semaglutide/north-carolina/{city}
§ 03Getting Semaglutide in Sanford
25 providers · Sanford, NC

How to get Semaglutide in Sanford.

25 GLP-1 prescribers and 5 local resource types are on record for Sanford, plus 3 nearby towns in the directory.

Prescribers in Sanford
25 prescribers
25 GLP-1 prescribers in Sanford, most listed as Family Medicine (15) and Internal Medicine (10). Any North Carolina-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Apex (28 providers), Cary (29 providers) and Fayetteville (35 providers).
Around the prescription in Sanford
5 listed nearby
15 dietitians, 6 gyms, 6 fitness clubs, 4 trainers and 6 physiotherapists are on record near Sanford.
Medicaid (weight loss)
Covered
As of April 2026, North Carolina Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Sanford

Sanford, North Carolina has a population of 30,261 people. The adult obesity rate in Sanford is an age-adjusted estimate of 39.8%, 5.3 percentage points above the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 13.4% of adults in Sanford. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 30.1% of adults in Sanford.

of Sanford adults have obesity
39.8%
diagnosed diabetes
13.4%
no regular physical activity
30.1%

Age-adjusted estimates for Sanford, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossthe GLP-1 side-effect timeline
§ 05Support around Semaglutide in Sanford
6 fitness clubs

The prescription is one part. Here is the rest, in Sanford.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Sanford, NC, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

S.L.A.M. Sweat Like A Mother Cameron-Sanford
FITNESS
5.0 on Google · 30 reviews
10891 NC-27
Website
Patient Warrior Fitness
FITNESS
5.0 on Google · 17 reviews
1915 Bragg St
Website
Planet Fitness
GYM
4.6 on Google · 662 reviews
2507 S Horner Blvd
Website
HiTONE Fitness
GYM
4.4 on Google · 125 reviews
2045 S Horner Blvd
Website
Ingram Family YMCA
FITNESS
4.4 on Google · 53 reviews
1907 K M Wicker Memorial Dr
Website
Fit for the purpose & more LLC
TRAINING
5.0 on Google · 41 reviews
1013 Woodyhill Ln
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Tara Buckley, RD
RD
Registered dietitian
120 Trail Rider Ln
Call 919-935-6050NPI 1467414979
Lori Gooch, RDN
RD
Registered dietitian
165 Wood Run
Call 719-339-9728NPI 1659135366
Nile Harris, RDN, LDN
RD
Registered dietitian
2300 Ramsey St
Call 910-488-2120NPI 1780567032
Amanda Hopkins, MS, RD, LDN
RD
Registered dietitian
4207 Lake Boone Trl Ste 210
Call 919-784-7874NPI 1639687403
Callie Huneycutt, RD, LDN
RD
Registered dietitian
15 Regional Dr
Call 910-235-3492NPI 1144767815
Jacklyn Kim, RDN, CDN
RD
Registered dietitian
500 Westover Dr # 19431
Call 512-693-7045NPI 1649111345
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in North Carolina

NPI-verified Semaglutide (semaglutide) prescribers and clinics, never ranked by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in North Carolina

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]